U
UTHR
United Therapeutics Corporation Common Stock
$540.03
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of United Therapeutics Corporation Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
$27.96
P/E
17.8
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Before the open · Expected EPS: $6.66
Nov 4
Posts
No posts about UTHR yet.
About United Therapeutics Corporation Common Stock
United Therapeutics develops and sells drugs for rare lung and blood vessel diseases, mainly pulmonary arterial hypertension, which is high blood pressure in the arteries of the lungs. Its main products are Tyvaso, Remodulin and Orenitram, all built around the drug treprostinil, and patients take them on a long-term basis. The company also runs research programs in organ manufacturing and transplant technology.